比较 HER2 低表达和 HER2 零表达乳腺癌的临床病理特征和新辅助化疗反应。
Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer.
机构信息
Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhong Shan Er Lu, Guangzhou, 510080, China; Laboratory of Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhong Shan Er Lu, Guangzhou, 510080, China.
Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhong Shan Er Lu, Guangzhou, 510080, China.
出版信息
Breast. 2023 Feb;67:1-7. doi: 10.1016/j.breast.2022.12.006. Epub 2022 Dec 14.
Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopathological data of 325 patients with stage I-III HER2 negative breast cancer who received neoadjuvant chemotherapy in the First Affiliated Hospital of Sun Yat-sen University from January 2016 to June 2021. In general, 91 patients (28.0%) were HER2-zero, and 234 patients (72.0%) were HER2-low. The pathological complete response (pCR) rate of the entire cohort was 17.3%. The pCR rate was 16.7% in HER2-low group, and 18.9% in HER2-zero group, showing no significant difference. Patients with HER2-low tumors had significantly longer overall survival (OS) than patients with HER2-zero tumors. ER status was the affecting factor of OS in HER2-low patients in both univariate and multivariate analysis. In conclusion, evidence for HER2-low BC as a distinct entity is insufficient, and more efforts are needed to standardize the scoring of HER2-low breast cancer.
新型抗 HER2 抗体-药物偶联物曲妥珠单抗 deruxtecan（DS-8201a）在先前治疗过的 HER2 低转移性乳腺癌中显示出疗效，这表明它在 HER2 低乳腺癌中有广阔的应用前景。我们回顾性分析了 2016 年 1 月至 2021 年 6 月中山大学附属第一医院收治的 325 例 I-III 期 HER2 阴性乳腺癌患者的临床病理资料。一般来说，91 例（28.0%）患者为 HER2 零状态，234 例（72.0%）患者为 HER2 低状态。全队列的病理完全缓解（pCR）率为 17.3%。HER2 低状态组的 pCR 率为 16.7%，HER2 零状态组为 18.9%，差异无统计学意义。HER2 低状态肿瘤患者的总生存期（OS）明显长于 HER2 零状态肿瘤患者。在单因素和多因素分析中，ER 状态均为 HER2 低状态患者 OS 的影响因素。总之，HER2 低 BC 作为一种独特实体的证据不足，需要进一步努力规范 HER2 低乳腺癌的评分。
Zotero 插件